January 28, 2016

Trillium Therapeutics Acquires Fluorinov Pharma

Combined entity creates strong foundation for leading Canadian immuno-oncology company

FACIT LogoTORONTO, ON (January 28, 2016) – FACIT has announced that Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR; “Trillium”) has acquired all of the outstanding shares of privately-held Fluorinov Pharma Inc. (“Fluorinov” or the “Company”), a FACIT portfolio company. The transaction combines Fluorinov’s pipeline of oncology therapeutics and risk-reduced drug discovery engine, with Trillium’s pool of innovative immuno-oncology therapies. The resulting impressive arsenal of clinical and near-clinical stage products is positioned to benefit greatly from the capital and development resources available to Trillium. The acquisition also reflects the strength of innovation within the province, as well as the current momentum behind biotechnology and product development expertise in Ontario.

Continue reading – Trillium Therapeutics Acquires Fluorinov Pharma